Toxicological Evaluation of Electronic Nicotine Delivery Products

Erscheinungsjahr 2021
ISBN: 978-0-12-820490-0
Verlag: Elsevier Science

Buch, Englisch, 620 Seiten, Format (B × H): 191 mm x 234 mm, Gewicht: 1247 g

Toxicological Evaluation of Electronic Nicotine Delivery Products (ENDP) discusses the scientific basis for the toxicological assessment and evaluation of ENDPs. The book covers aerosol chemistry, in vitro and in vivo studies as well as clinical studies. It provides the basis for the evaluation of short and long term-effects, along with relative risks. It also examines the potential role of ENDPs in tobacco harm reduction and how they may reduce the risk of disease in smokers who switch to them. This book is a comprehensive resource for toxicologists, health practitioners and public health professionals who want the scientific information necessary to assess the relative risk of ENDPs when compared with cigarette smoking and cessation.

Zielgruppe

<p>: Toxicologists (academia, regulatory authorities and industry); Public health professionals (academia, government)</p>

Autoren/Hrsg.

Peitsch, Manuel C.

Hoeng, Julia

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Public Health, Gesundheitsmanagement, Gesundheitsökonomie, Gesundheitspolitik

Inhaltsverzeichnis

1. Tobacco Harm Reduction
2. Electronic nicotine delivery devices (ENDS)
3. The scientific basis for the assessment of ENDS
4. Quantification of HPHC in ENDS aerosols
5. Aerosol physics and dynamics
6. Advanced analytical chemistry methods to characterize ENDS aerosols
7. Other species of toxicological concern
8. Impact of ENDS on indoor air quality
9. A systems-based approach to toxicity testing
10. Translational aspects of toxicity testing
11. Dosimetry and human-relevant exposure
12. Aerosol generation, exposure, and collection
13. Toxicological assessment in vitro
14. Toxicological assessment in vivo
15. Assessment of in vivo models of disease
16. Flavors and their toxicological assessment
17. A clinical strategy for ENDS testing
18. The disease risk reduction potential of ENDS
19. Residual risk associated to nicotine
20. Conclusion

Über Autor(innen)

Peitsch, Manuel C.
Dr. Peitsch is Chief Scientific Officer and VP of Research and Development at Philip Morris International. He has extensive experience in tobacco harm reduction, smoking-related diseases, systems biology, toxicology, bioinformatics, chemoinformatics, high-performance computing, and knowledge management. An innovation-focused results-driven biomedical research leader, Dr. Peitsch has many years of experience managing large multi-cultural teams across several countries. He holds several patents related to proteomics, genomics, and computer science and has published over 200 book chapters, technical reports, and articles in top ranking scientific journals (cited over 22000 times). He has done pioneering work in the area of molecular modeling, cell biology, computational text analytics, and systems biology/toxicology and is a founder of several initiatives, including two start-up companies, the Swiss Institute of Bioinformatics, and the [BC]2 conference (http://www.bc2.ch). He is Chairman of the Executive Board of the Swiss Institute of Bioinformatics and an active scientific advisor to several academic and commercial entities. He has also served on the Swiss National Research Council. Dr. Peitsch is a Computerworld Honors Laureate and a recipient of several awards including the New England Business and Technology Award and the United Devices Grid Visionary Award. He holds a BSc in life sciences, MSc in physical chemistry, and PhD in biochemistry. He is also Professor of Bioinformatics at the University of Basel.

Hoeng, Julia
Dr. Hoeng is Director of Systems Biology at Phillip Morris International and program leader. She has a profound understanding of inhalation toxicology and computational modeling of smoking-related diseases, lung cancer, COPD, and CVD. Dr. Hoeng holds a BSc in biology, MSc in bioinformatics, PhD in protein crystallography, and an executive MBA.